2,4-二氨基嘧啶类化合物及其应用
By designing selective JAK1 inhibitors, specifically 2,4-diaminopyrimidine compounds, the side effects of existing pan-JAK inhibitors have been addressed, achieving both high-efficiency treatment and improved safety for JAK1-related diseases.
CN119954777BActive Publication Date: 2026-07-17SHENYANG PHARMA UNIV +1
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- SHENYANG PHARMA UNIV
- Filing Date
- 2025-01-03
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
Existing pan-JAK inhibitors carry risks of thrombosis, heart problems, and serious infections with long-term use, and have poor selectivity, failing to effectively reduce side effects.
Method used
To develop a selective JAK1 inhibitor, specifically a 2,4-diaminopyrimidine compound, that targets JAK1 through the design of compounds with specific structures, thereby reducing the impact on other members of the JAK family.
Benefits of technology
It significantly reduces the risk of side effects, improves the selectivity and safety of treating JAK1-related diseases, and reduces the risk of thrombosis and infection.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN119954777B_ABST
Abstract
本发明涉及药物化学领域，特别涉及一种2,4‑二氨基嘧啶类化合物及其用于制备治疗和 / 或预防由JAK家族介导的疾病的药物中的应用。化合物为通式Ⅰ所示的化合物、其立体异构体及其药学上可接受的盐，其中取代基R1、R2、L和环A具有在说明书中给出的含义。本发明还涉及通式Ⅰ的化合物在制备治疗和 / 或预防由JAK家族介导的疾病的药物中的应用。
Need to check novelty before this filing date? Find Prior Art